EpiHERA

Early Endometrial Cancer Detection Technology

epiHERA™ is a minimally invasive early endometrial cancer detection test that identifies methylated biomarkers which give indications press ion from malignancy.

Designed to address unmet clinical needs where:

Use less painful collection compared to Dilation & Curettage & Pipelle Biopsy.

Molecular test hence less variability as seen in histopatholical testing.

Get results in 2 days instead of weeks from usual pathology lab.

Integration into clinical workflows:

Investigate abnormal uterine bleeding in pre and post-menopausal women.

Effectively differentiate between benign and malignancy.

Pre-operative clinical decisions and monitoring.

Clinical Validation of epiHERA®:

Sensitivity: 86.7%

Specificity: 100.0%

PPV: 100.0%

NPV: 98.9%

Advantages:

Collection using ThinPrep®.

No surgical setup for sample collection.

Easy and simple qPCR runEasy

EpiHERA

EpiHERA

Designed to address unmet clinical needs where:

Integration into clinical workflows:

Clinical Validation of epiHERA®:

Advantages:

FOLLOW US

Quick Contact

Get in Touch

Designed By Credes Technologies Pvt. Ltd.